Amendment to Collaboration and License AgreementCollaboration and License Agreement • April 22nd, 2014 • Epizyme, Inc. • Pharmaceutical preparations
This Amendment (this “Amendment”) to the Collaboration and License Agreement dated as of February 20, 2014 and previously amended on July 23, 2013 (collectively, the “Agreement”), by and between EPIZYME and GSK is effective as of the date of last signature below (the “Amendment Effective Date”). Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Agreement.
Amendment No. 3 to Collaboration and License AgreementCollaboration and License Agreement • April 22nd, 2014 • Epizyme, Inc. • Pharmaceutical preparations
This Amendment No. 3 (this “Amendment No. 3”) to the Collaboration and License Agreement dated as of January 8, 2011 and previously amended on July 23, 2013 and February 24, 2014 (as so amended, the “Agreement”), by and between Epizyme, Inc., a Delaware corporation having its principal place of business at 400 Technology Square, 4th Floor, Cambridge, Massachusetts 02139 USA (“EPIZYME”) and Glaxo Group Limited, a company existing under the laws of England, having its registered office at Glaxo Wellcome House, 980 Great West Road, Brentford, Middlesex, TW8 9GS, England (“GSK”) is effective as of March 18, 2014 (the “Amendment No. 3 Effective Date”). Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Agreement.
